Showing results (1001-1010 of 1,842) with videos related to

Sort By:
Pageof 185
ESMO Open|August 11, 2018
Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicityShin Hye Yoo, Bhumsuk Keam, Miso Kim, et al.
ESMO Open|August 11, 2018
High incidence of cetuximab-related infusion reactions in head and neck patientsVirginia Palomar Coloma, Pamela Bravo, Naima Lezghed, et al.
ESMO Open|August 11, 2018
Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeuticJean-François Baurain, Caroline Robert, Laurent Mortier, et al.
ESMO Open|August 11, 2018
Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancerChristian Rolfo, Paolo Manca, Roberto Salgado, et al.
ESMO Open|July 19, 2018
Indicators of integration at ESMO Designated Centres of Integrated Oncology and Palliative CareDavid Hui, Nathan I Cherny, Jimin Wu, et al.
ESMO Open|May 17, 2018
Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancerRichard M Goldberg, Clara Montagut, Zev A Wainberg, et al.
ESMO Open|May 2, 2018
Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data setAxel Grothey, Takayuki Yoshino, Gyorgy Bodoky, et al.
ESMO Open|November 18, 2020
Completion rate and impact on physician-patient relationship of video consultations in medical oncology: a randomised controlled open-label trialThomas Walle, Erkin Erdal, Leon Mühlsteffen, et al.
ESMO Open|November 19, 2020
An evaluation of self-perceived knowledge, attitudes and behaviours of UK oncologists about LGBTQ+ patients with cancerAlison May Berner, Daniel Johnathan Hughes, Hannah Tharmalingam, et al.
ESMO Open|November 6, 2020
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trialMatteo Lambertini, Dominique Agbor-Tarh, Otto Metzger-Filho, et al.
Pageof 185